26国103个ICU中免疫功能低下患者急性呼吸衰竭的流行病学、通气策略与结局:一项回顾性观察研究
该回顾性观察研究纳入2017年1月1日至2023年12月31日期间26个国家103个ICU收治的9854例免疫功能低下合并急性呼吸衰竭成人患者,主要免疫缺陷原因为血液系统恶性肿瘤(48.3%)和实体瘤(38.7%),感染是急性呼吸衰竭首位病因(62.0%)。30天死亡率为47.3%。校正后死亡风险升高相关因素包括入ICU时昏迷(HR 2.04)、未明确病因(HR 2.16)、使用血管活性药物(HR 2.45)和肾脏替代治疗(HR 2.07);实体器官移植(HR 0.62)、较高的PaO2/FiO2比值(HR 0.78)和接受经鼻高流量氧疗(HR 0.78)与较低死亡风险相关。作者认为这些发现可能通过辅助及时临床决策、治疗目标讨论和管理改善该脆弱人群的结局。
要点
- 9854例免疫功能低下合并急性呼吸衰竭患者30天死亡率为47.3%(4662例)。
- 入ICU时昏迷与死亡风险升高相关(HR 2.04,95%CI 1.72-2.43)。
- 未明确急性呼吸衰竭病因者死亡风险更高(HR 2.16,95%CI 1.74-2.68)。
- 使用血管活性药物(HR 2.45,95%CI 2.10-2.86)和肾脏替代治疗(HR 2.07,95%CI 1.74-2.48)与死亡风险升高相关。
- 接受经鼻高流量氧疗与较低死亡风险相关(HR 0.78,95%CI 0.64-0.95)。
适用人群与场景
- 纳入标准:年龄≥18岁、入住参与ICU的免疫功能低下合并急性呼吸衰竭患者。
- 主要免疫缺陷原因为血液系统恶性肿瘤(4759/9854,48.3%)和实体瘤(3818/9854,38.7%)。
- 场景为26个国家103个ICU的成人患者,研究期间为2017年1月1日至2023年12月31日。
红旗征与不能漏的情况
- 入ICU时昏迷与死亡风险升高相关(HR 2.04,95%CI 1.72-2.43)。
- 未明确急性呼吸衰竭病因与死亡风险升高相关(HR 2.16,95%CI 1.74-2.68)。
- 使用血管活性药物与死亡风险升高相关(HR 2.45,95%CI 2.10-2.86)。
- 使用肾脏替代治疗与死亡风险升高相关(HR 2.07,95%CI 1.74-2.48)。
研究设计与关键结果
- 研究类型:回顾性观察研究;样本量9854例;103个ICU;26个国家;人群为免疫功能低下合并急性呼吸衰竭成人患者。
- 30天死亡率为47.3%(4662例);中位PaO2/FiO2比值为198(IQR 141-208)。
- 死亡风险升高相关因素:年龄较大(HR 1.01,95%CI 1.00-1.02)、Charlson合并症指数较高(HR 1.04,95%CI 1.01-1.07)、衰弱指数较高(HR 1.22,95%CI 1.16-1.28)、从入院至入ICU时间较长(HR 1.02,95%CI 1.01-1.03)、呼吸频率较高(HR 1.02,95%CI 1.02-1.03)、入ICU时昏迷(HR 2.04,95%CI 1.72-2.43)、侵袭性真菌感染为急性呼吸衰竭病因(HR 1.82,95%CI 1.45-2.28)、疾病特异性浸润影(HR 1.73,95%CI 1.32-2.26)、未明确急性呼吸衰竭病因(HR 2.16,95%CI 1.74-2.68)、使用血管活性药物(HR 2.45,95%CI 2.10-2.86)、使用肾脏替代治疗(HR 2.07,95%CI 1.74-2.48)。
- 死亡风险降低相关因素:接受实体器官移植(HR 0.62,95%CI 0.49-0.79)、系统性血管炎或结缔组织病(HR 0.61,95%CI 0.47-0.78)、较高的PaO2/FiO2比值(HR 0.78,95%CI 0.72-0.84)、接受经鼻高流量氧疗(HR 0.78,95%CI 0.64-0.95)、心源性肺水肿(HR 0.67,95%CI 0.51-0.89)。
- 急性呼吸衰竭首位病因为感染(6610/9854,62.0%);5288例(53.7%)有超过一个病因;1490例(15.1%)未明确病因。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现可能通过辅助及时临床决策、治疗目标讨论和管理改善该脆弱人群的结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute hypoxaemic respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admission among immunocompromised patients. However, contemporary data regarding the epidemiology, management, and outcomes of ARF in this population remain scarce. We aimed to identify predictors of mortality and intubation in immunocompromised patients admitted to the ICU with ARF.
METHODS: This retrospective observational study was conducted in 103 ICUs in 26 countries. Adults (≥18 years) with ARF and immunodeficiency were eligible for inclusion. Patient data, including information on the nature of underlying immunosuppression, the cause of ARF, and the oxygenation strategy, were obtained from electronic medical records or medical charts. The primary outcome was to report 30-day mortality and identify associated factors in patients with complete data for all variables. Cox proportional hazards models were used to identify variables associated with mortality, and differences between groups were compared with χ2 tests or two-sided Wilcoxon rank-sum tests, with p values of less than 0·05 considered significant.
FINDINGS: 9854 immunocompromised patients with ARF admitted to participating ICUs between Jan 1, 2017, and Dec 31, 2023, were included in the study. The median age was 64 years (IQR 54-71); 3941 (40·0%) patients were female and 5913 (60·0%) were male. The main causes of immunodeficiency were a haematological malignancy (4759 [48·3%] of 9854 patients) or solid malignancy (3818 [38·7%] patients). Infection was the leading cause of ARF (6610 [62·0%] of 9854 patients); 5288 (53·7%) patients had more than one contributing cause of ARF, and no cause was identified in 1490 (15·1%) patients. The median partial pressure of oxygen in arterial blood (PaO2)/fractional concentration of oxygen in inspired air (FiO2) ratio was 198 [IQR 141-208]. The 30-day mortality rate was 47·3% (4662 patients). Predictors of higher mortality were older age (hazard ratio 1·01 [IQR 1·00-1·02]), higher Charlson Comorbidity Index score (1·04 [1·01-1·07]), higher Frailty Index score (1·22 [1·16-1·28]), longer time from hospital to ICU admission (1·02 [1·01-1·03]), higher respiratory rate (1·02 [1·02-1·03]), coma at ICU admission (2·04 [1·72-2·43]), invasive fungal infection as cause of ARF (1·82 [1·45-2·28]), disease-specific infiltrates (1·73 [1·32-2·26]), unidentified cause of ARF (2·16 [1·74-2·68]), and use of vasoactive drugs (2·45 [2·10-2·86]) or renal replacement therapy (2·07 [1·74-2·48]). Protective factors included receipt of a solid organ transplant (0·62 [0·49-0·79]), systemic vasculitis or connective tissue disease (0·61 (0·47-0·78]), higher PaO2/FiO2 ratio (0·78 [0·72-0·84]), receipt of high-flow nasal oxygen therapy (0·78 [0·64-0·95]), and cardiogenic pulmonary oedema (0·67 [0·51-0·89]).
INTERPRETATION: In this large international cohort of immunocompromised patients with ARF, we identified key risk and protective factors for mortality and intubation. These findings could improve outcomes by informing timely clinical decisions, goals-of-care discussions, and management in this vulnerable population.
FUNDING: Kirsten and Freddy Johansen Foundation and Groupe de Recherche en Réanimation Onco-Hématologique.
参考来源
- Azoulay E, McEvoy C, Castro P, et al. Epidemiology, ventilation, and outcomes of acute respiratory failure in immunocompromised patients from 103 intensive care units in 26 countries: a retrospective observational study. Lancet Respir Med. 2026. PMID: 41856149. doi:10.1016/S2213-2600(26)00046-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。